GBT021601-022: A Study of GBT021601 in Participants With Sickle Cell Disease (SCD)

Retrospective Real World Oxbryta® Data Collection and Analysis Study

NCT04930328 ·Status: COMPLETED

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

NCT02151526 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Losartan for Diffuse Myocardial Fibrosis in Sickle Cell Disease

NCT05012631 ·Status: RECRUITING ·Phase: PHASE2

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT06546670 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

NCT05904093 ·Status: RECRUITING ·Phase: PHASE1

A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease

NCT03132324 ·Status: TERMINATED ·Phase: PHASE1

A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

NCT02140554 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

NCT04255875 ·Status: COMPLETED ·Phase: PHASE1

Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)

NCT04443907 ·Status: TERMINATED ·Phase: PHASE1

A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants

NCT01745120 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and India

NCT05020873 ·Status: TERMINATED

Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy

NCT04628585 ·Status: ENROLLING_BY_INVITATION

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

NCT03285178 ·Status: COMPLETED ·Phase: PHASE2

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

NCT02433158 ·Status: TERMINATED ·Phase: PHASE3

A Study Evaluating the Long-Term Safety of ICA-17043 in Sickle Cell Disease Patients With or Without Hydroxyurea Therapy

NCT00294541 ·Status: TERMINATED ·Phase: PHASE3

ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene

NCT01639690 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

An Extension Study of IMR-687 in Adult Patients With Sickle Cell Anemia

NCT04053803 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease

NCT06399107 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects

NCT02497924 ·Status: COMPLETED ·Phase: PHASE1

A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

NCT04293185 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031 ·Status: WITHDRAWN ·Phase: PHASE1

CS-206 in Patients With Sickle Cell Disease

NCT07000318 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1

Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

NCT05145062 ·Status: ACTIVE_NOT_RECRUITING

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

NCT06975865 ·Status: RECRUITING ·Phase: PHASE3

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

NCT06363760 ·Status: ENROLLING_BY_INVITATION